CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.20760164

Available online at: http://www.iajps.com Review Article

COMPREHENSIVE REVIEW OF MIGRAINE: EVOLUTION, DIAGNOSTICS, BIOMARKERS, AND THERAPEUTIC ADVANCEMENTS

Jismi Jackson [1], Dr. T. Tamilselvan [2], Asika Dileep [3], Athira Sajeev [3], Betty George [3], Honey Mariya Babu [3], Kadeejathul Hana K P [3], Nimitha K Rajan [3]

[1]Fourth Semester, M Pharm Student, Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588
[2]HOD & Professor, Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588
[3] Fourth Semester, M Pharm Students, Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588

Abstract:
Migraine is a very common, complicated neurovascular condition that seriously impairs people all over the world. Emerging evolutionary models indicate that migraine attacks function as a conserved protective mechanism when environmental stressors exceed a physiological threshold, resulting in pain and sickness behaviour that necessitates a complete reduction in activity to enable a metabolically vulnerable, hyper-excitable brain to restore its homeostatic energy reserves. This goes beyond a straightforward sensory defect. This narrative review connects evolutionary biology, unique clinical characteristics, precise circulating biomarkers, and cutting-edge therapeutics to present a succinct, multifaceted overview of migraine therapy. A total of thirty seminal publications were methodically chosen and incorporated based on clinical significance after a thorough search of the PubMed, MEDLINE, and Google Scholar databases for peer-reviewed review articles, meta-analyses, and clinical guidelines published up until 2026. The information gained shows that targeted molecular preventatives (such as anti-CGRP monoclonal antibodies) must be combined with lifestyle nutraceuticals (like magnesium), physical therapy, and patient-centred communication in order to provide modern migraine management. In this multidisciplinary matrix, the clinical pharmacist is essential for therapeutic drug monitoring, medication reconciliation, and enforcing stringent guidelines to prevent medication overuse headaches (MOH). Additionally, by screening for cardiovascular contraindications and limiting the use of oestrogen-containing contraceptives in high-risk female patients, pharmacists reduce the risk of long-term ischemic stroke. In order to maximize clinical outcomes and enhance overall quality of life, they efficiently assess the cost-effectiveness of cutting-edge biological treatments, manage localized injection-site adverse effects, and optimize long-term patient adherence to innovative therapies by proactive counselling.
KEYWORDS: *Migraine Pathophysiology, Evolutionary Biology, Trigeminovascular System, Circulating Biomarkers, Cortical Hyperexcitability, Targeted Anti-CGRP Therapeutics*

Corresponding author:
Jismi Jackson,
4th Semester, M. Pharm Students,
Department of Pharmacy Practice,
Nehru College of 2Pharmacy,
Thiruvilwamala, Thrisssur, 680588

QR CODE

Please cite this article in press Jismi Jackson et al., Comprehensive Review Of Migraine: Evolution, Diagnostics, Biomarkers, And Therapeutic Advancements, Indo Am. J. P. Sci, 2026; 13(06).

INTRODUCTION:

About one in eight people suffer from migraine, a widespread neurovascular condition that causes excruciating, throbbing headache attacks along with sensory sensitivity that significantly lowers health-related quality of life (HRQoL) [11]. Modern research redefines migraine as a neurovascular continuum caused by main brain malfunction, driven by an inter-ictal state of cortical hyperexcitability and underlying metabolic or mitochondrial vulnerabilities [3]. Previously, migraine was considered primarily a vascular constriction issue. The Trigeminovascular system becomes activated and sensitive when cumulative allostatic stressors surpass a certain neurological threshold (4). This causes the trigeminal nerve endings to release a cascade of vasoactive neuropeptides into the Dural vasculature, primarily Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) [6]. Importantly, new philosophical and Darwinian theories contend that these severe instances are not the result of spontaneous biological flaws [29]. Instead, a persuasive school of thinking sees migraine attacks as an evolutionarily conserved, protective defence mechanism [1]. The incapacitating pain, sensory aversion, and ensuing illness behaviour have an adaptive function: they compel an instantaneous, complete decrease in mental and physical effort, enabling the worn-out central nervous system to replenish its critically depleted homeostatic energy stores. However, this mechanism develops into chronic migraine when it becomes maladaptively hyperactive as a result of ongoing environmental stress or genetic predisposition, turning a survival alarm into a harmful, systemic illness [12]. Modern clinical pharmacy practice must go beyond standard acute symptomatic relief and adopt a multi-modal strategy connecting advanced targeted pharmacotherapies, precision circulating biomarkers, and evolutionary knowledge in order to provide an optimum care matrix [22,23].

LITERATURE SEARCH STRATEGY

PubMed, MEDLINE, and Google Scholar were the sources of the literature used in this review. Using keywords like "migraine pathophysiology," "evolutionary meaning of migraine," "Trigeminovascular system," "circulating biomarkers," "vestibular migraine," "anti-CGRP monoclonal antibodies," and "magnesium in migraine," the search focused on high-impact peer-reviewed reviews, meta-analyses, and observational studies published up until 2026. The International Classification of Headache Disorders (ICHD) criteria, clinical relevance, and contribution to contemporary precision therapies were taken into consideration when screening articles.

PATHOPHYSIOLOGY AND EVOLUTIONARY BIOLOGY OF MIGRAINE

Mitochondrial / Energy Deficit in Brain
|
Cortical Hyperexcitability
|
Environmental / Allostatic Stress Triggers
|
Trigeminovascular System Activation (CGRP Release)
|
Pain, Sensory Hypersensitivity, Forced Rest
|
Evolutionary Goal: Brain Homeostasis Restored

THE DARWINIAN PARADOX AND ADAPTIVE DEFENSE MECHANISMS

The evolutionary preservation of migraine susceptibility genes suggests the disorder is a conserved adaptation rather than a random genetic flaw [1]. In the inter-ictal phase, the migraineur's brain exhibits cortical hyperexcitability and a low sensory threshold, creating heightened sensitivity to subtle environmental shifts—an attribute that likely provided survival advantages in ancestral environments [3].

However, when sensory or metabolic demands exceed the brain's energetic capacity, a protective shutdown sequence is triggered [1]. The resulting severe pain and sensory aversions (photophobia and phonophobia) force individual isolation and halt physical and cognitive output [1, 11]. This induced "sickness behaviour" acts as an evolutionary mandate that minimizes metabolic consumption,

redirecting body resources to restore homeostatic neural balance and reverse cellular stress [1].

THE TRIGEMINOVASCULAR FRAMEWORK

The primary mechanism that converts brain tension into a headache is the Trigeminovascular system [4]. It links the blood vessels that cover the brain (the dura mater) to the brain's nerves. These nerve terminals emit chemical messengers, primarily Calcitonin Gene-Related Peptide (CGRP), when a migraine is induced [6]. There are two primary effects of this release on the blood arteries.

- **Vasodilation:** The blood vessels widen significantly [4].
- **Neurogenic Inflammation:** The area becomes inflamed and irritated [6].

These irritated vessels send continuous pain signals back to the brain's pain centres (the thalamus and cortex), creating the classic throbbing migraine headache [4].

DIAGNOSTIC HETEROGENEITY AND CLINICAL PHENOTYPES

Significant clinical heterogeneity characterizes migraine, which manifests as a wide range of overlapping symptoms and sensory abnormalities rather than as a single illness entity

.

TABLE 1: TYPES OF MIGRAINE

Type of Migraine	Important Pathophysiological and Diagnostic Elements Principal Clinical Difficulties
Migraine without Aura	Attacks are recurrent, pulsing, unilateral, moderate-to-severe in intensity, and exacerbated by physical exertion; they last 4–72 hours. monitoring medication usage and distinguishing from tension-type headaches.
Migraine with Aura	Reversible localized neurological symptoms that last less than 60 minutes and emerge over a period of five to twenty minutes (visual, sensory, or verbal).
Vestibular Migraine	There is a high correlation between migraine symptoms and episodic vertigo, dizziness, and motion sensitivity; these symptoms may not be present at all.
Menstrual Migraine	Attacks are invariably associated with the abrupt luteal oestrogen depletion that occurs just before menstruation.

VESTIBULAR AND MOTION MANIFESTATIONS

Trigeminal pain networks and central vestibular pathways interact in vestibular migraine, a unique clinical variation [3]. Patients may have severe motion sickness, postural instability, and episodic vertigo without a headache. This occurs as a result of a shared hyperresponsiveness between the vestibular (balance) and nociceptive (pain) areas of the brainstem. To guarantee an accurate diagnosis and avoid needless, unsuccessful ear treatments, it is essential to recognize this shared mechanism.

COMPLICATED VARIANTS AND OCULAR SHIFTS

Retinal, hemiplegic, and status migrainosus variations are examples of complicated migraines that involve neurological impairments that go well beyond simple headaches [3].

The choroidal layer in the eye is significantly thinned in chronic migraineurs, according to recent optical diagnostics using SD-OCT (Spectral-Domain Optical Coherence Tomography) [5]. This structural thinning provides a rapid, non-invasive method of monitoring the patient's vascular state and demonstrates how migraine microvascular alterations systematically affect the eye [5].

PRECISION MEDICINE AND CIRCULATING BIOMARKERS

Finding and detecting particular circulating molecular biomarkers is essential to the shift from empirical, trial-and-error migraine treatment to precision therapy.



CALCITONIN GENE-RELATED PEPTIDE (CGRP)

CGRP is widely recognized as the most important biomarker in current migraine neurobiology. The trigeminal ganglion contains a high concentration of this 37-amino acid neuropeptide. During an acute migraine attack, plasma concentrations of CGRP rise dramatically and are strongly correlated with the intensity of the pain. After successful abortive medication, these levels return to normal. Clinicians can screen patients who will benefit most from specific treatment regimens by measuring baseline peripheral CGRP levels, which act as a predictive indicator for therapy responses.

EMERGING SYSTEMIC BIOMARKERS

In addition to CGRP, precision medicine monitors several circulating molecules to evaluate vascular health and neuro-inflammation:

- **PACAP:** A strong neuromodulator and vasodilator that regularly causes migraine headaches in vulnerable people [(6)].
- Chronic migraineurs have higher levels of **Inflammatory Cytokines (IL-6 and TNF-alpha),** which indicate persistent, low-grade neurogenic inflammation [(6)].
- **Adipokines (Adiponectin & Leptin):** The primary biochemical connection between metabolic syndrome, obesity, and migraine chronification is provided by altered levels [(8)].

CARDIOVASCULAR AND CEREBROVASCULAR COMPLICATIONS

The Relationship Between Migraine and Stroke

Migraine, particularly migraine with aura, is strongly associated with an elevated risk of ischemic stroke, according to epidemiological evidence [(10).] Chronic endothelial dysfunction, microvascular blood clotting, and recurrent bouts of cortical spreading depression (CSD) put patients at risk for localized reductions in cerebral blood flow [(10,15)].

Before providing long-term treatments, thorough cardiovascular risk screening is crucial because the risk of stroke increases dramatically in female patients who smoke or use oral contraceptives containing oestrogen [(15,18)].

Systemic Vascular Spasms

Rarely is migraine's neurovascular instability limited to the intracranial vasculature. Clinical overlaps point to a common pathogenesis with systemic vasospastic diseases, including angina pectoris brought on by coronary artery spasms and Raynaud's phenomenon. This implies that smooth muscle walls in several vascular beds are vulnerable to abrupt, hyperresponsive constrictions due to a widespread, systemic endothelial hyper-reactivity.

THERAPEUTIC ADVANCEMENTS AND MULTI-MODAL MANAGEMENT

MIGRAINE TREATMENT MATRIX

Targeted molecular	Nutraceutical Loading	Conservative Physical
Anti-CGRP mAbs	Magnesium (400-600mg)	Manual Therapy
Small-molecule	Dietary Trigger Avoidance	Trigger Point Release
Gepants / Ditans		

TARGETED MOLECULAR MEDICATION

In contrast to conventional, non-specific beta-blockers or tricyclic antidepressants, targeted molecular medicines provide excellent specificity:

Anti-CGRP Monoclonal Antibodies (mAbs): Long-acting prophylaxis with little side effects is offered by agents such as Eranumab (receptor blocker) and Fremanezumab, Galcanezumab, or Eptinezumab (ligand blockers) [22].

Gepants (CGRP Receptor Antagonists): Oral medications, such as Ubrogepant and Rimegepant, are safer for cardiovascular patients since they prevent acute episodes without inducing the severe blood vessel narrowing associated with conventional triptans [22,23].

Ditans (5 -HT_{1F} Receptor Agonists): Lasmiditan stops the transmission of pain by carefully targeting central trigeminal nerve pathways without constricting peripheral blood vessels [23].

Nutraceutical And Dietary Interventions

Adding nutraceuticals to multimodal migraine treatment offers an efficient, low-toxicity layer:

Magnesium Supplementation: Oral use of 400–600 mg of citrate or glycinate per day maximizes mitochondrial energy generation, inhibits cortical spreading depression (CSD), and stabilizes NMDA glutamate receptors [24].

Dietary Counselling: Systematic tracking helps eliminate known chemical triggers—such as tyramine, nitrates, and artificial sweeteners—that actively disrupt vascular tone [24,25].

Conservative And Physical Therapy Modalities

By addressing musculoskeletal causes, physical therapy lowers the frequency of attacks [26]. Manual therapy, cervical spine mobilization, and myofascial trigger point releases in the suboccipital and trapezius muscles are examples of interventions [26, 27]. By reducing the constant pain signals that travel from the neck to the trigeminal nucleus caudates, this conservative method successfully ends the cycle of central sensitization [27].

CONCLUSIONS:

Migraine remains a complex neurovascular problem that connects intricate systemic illnesses with profound evolutionary adaptations. Modern neuroscience shows that a migraine episode functions as a highly conserved defence reaction intended to preserve an energy balance inside a hyper-excitable brain, rather from being a random cellular malfunction. Precision medicine must replace conventional, generic treatments in order to translate this neuro-metabolic mismatch into therapeutic activity. Monitoring particular circulating neurovascular indicators, such as CGRP, has made it possible to develop highly focused monoclonal antibodies and small-molecule antagonists that disrupt the sensory cascade without posing a risk to the cardiovascular system.

A multimodal matrix combining highly targeted molecular preventatives with lifestyle-focused nutraceutical loading (such magnesium), musculoskeletal physical therapy, and patient-centred communication models is necessary to optimize clinical outcomes.

The clinical pharmacist is an essential leader in this evolving neurological care paradigm. Clinical pharmacy interventions are essential for long-term patient rehabilitation and improved quality of life because they drive proactive electronic medical record scans, manage complex drug interactions, and enforce rigorous bounds to minimize medication overuse headaches.

REFERENCES:

1. Pensato U, Cevoli S, Pierangeli G, Cortelli P. The evolutionary meaning of migraine. Cephalalgia. 2023 Dec;43(12)
2. Buzzi MG, Cologno D, Formisano R. Migraine disease: evolution and progression. J Headache Pain. 2005 Sep;6(4):304-6
3. Cutrer FM, Smith JH. Human studies in the pathophysiology of migraine: genetics and

functional neuroimaging. Headache. 2013 Feb;53(2):401-12
4. Russo A, Tessitore A, Tedeschi G. Migraine and trigeminal system-I can feel it coming…. Curr Pain Headache Rep. 2013 Oct;17(10):367.
5. Chaturvedi P, Khan R, Sahu P, Ludhiadch A, Singh G, Munshi A. Role of Omics in Migraine Research and Management: A Narrative Review. Mol Neurobiol. 2022 Sep;59(9):5809-5834.
6. Ferroni P, Barbanti P, Spila A, Fratangeli F, Aurilia C, Fofi L, Egeo G, Guadagni F. Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine. Curr Med Chem. 2019;26(34):6191-6206
7. Johnson MP, Fernandez F, Colson NJ, Griffiths LR. A pharmacogenomic evaluation of migraine therapy. Expert Opin Pharmacother. 2007 Aug;8(12):1821-35.
8. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology. 1994 Jun;44(6 Suppl 4): S24-39.
9. Freedom T, Jay WM. Migraine with and without headache. Semin Ophthalmol. 2003 Dec;18(4):210-7
10. Rothner AD. Complicated migraine and migraine variants. Semin Pediatr Neurol. 2001 Mar;8(1):7-12.
11. Lipton RB, Stewart WF, Reed M, Diamond S. Migraine's impact today. Burden of illness, patterns of care. Postgrad Med. 2001 Jan;109(1):38-40, 43-5
12. Fernández-Bermejo E, Planchuelo-Gómez Á, Quintas S, Gonzalez-Martinez A, García-Azorín D, Sierra-Mencía Á, Guerrero ÁL, Santos-Lasaosa S, Navarro-Pérez MP, González-García N, Díaz-de-Terán J, Gago-Veiga AB. Evaluation of the burden of migraine on the partner's lifestyle. Neurologia (Engl Ed). 2024 Nov-Dec;39(9):810-819.
13. Furman JM, Marcus DA. Migraine and motion sensitivity. Continuum (Minneap Minn). 2012 Oct;18(5 Neuro-otology):1102-17.
14. Crevits L, Bosman T. Migraine-related vertigo: towards a distinctive entity. Clin Neurol Neurosurg. 2005 Feb;107(2):82-7.
15. Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: a diagnostic challenge. Cephalalgia. 2004 Feb;24(2):83-91.
16. Felisati G, Pipolo C, Portaleone S. Migraine and vertigo: two diseases with the same pathogenesis? Neurol Sci. 2010 Jun;31 Suppl 1: S107-9
17. Chen SP, Eikermann-Haerter K. How Imaging Can Help Us Better Understand the Migraine-Stroke Connection. Headache. 2020 Jan;60(1):217-228.
18. Welch KM. Relationship of stroke and migraine. Neurology. 1994 Oct;44(10 Suppl 7): S33-6.
19. Wöber-Bingöl C, Wöber A, Karwautz M, Feucht M, Brandtner S, Scheid Inger H. Migraine and stroke in childhood and adolescence. Cephalalgia. 1995 Feb;15(1):26-30
20. Guarani M, Salehi MA, Mohammadi S, Arevalo JF. Choroidal thickness in eyes of migraine patients measured using spectral domain-optical coherence tomography: A meta-analysis. Surv Ophthalmol. 2023 Jan-Feb;68(1):67-77
21. Lafitte C, Even C, Henry-Lebras F, de Toffol B, Autret A. Migraine and angina pectoris by coronary artery spasm. Headache. 1996 May;36(5):332-4
22. Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019 Jan;25(2 Suppl): S23-S34.
23. Tiwari R, Tiwari G, Mishra S, Ramachandran V. Preventive and Therapeutic Aspects of Migraine for Patient Care: An Insight. Curr Mol Pharmacol. 2023;16(2):147-160.
24. Varga P, Lehoczki A, Fekete M, Jarecsny T, Kryczyk-Poprawa A, Zábó V, Major D, Fazekas-Pongor V, Csípő T, Varga JT. The Role of Magnesium in Depression, Migraine, Alzheimer's Disease, and Cognitive Health: A Comprehensive Review. Nutrients. 2025 Jul 4;17(13):2216
25. Sun-Edelstein C, Mauskop A. Foods and supplements in the management of migraine headaches. Clin J Pain. 2009 Jun;25(5):446-52
26. Siverling S, Schultz P. A Multimodal Conservative Approach to Treating Migraine: A Physical Therapist's Perspective. Curr Pain Headache Rep. 2023 Sep;27(9):329-337.
27. Egodage UK, Mohideen MS, Mohotti SP. Sex differences in migraine: bridging pathophysiology and clinical care in women. Adv Physiol Educ. 2025 Dec 1;49(4):1109-1115.
28. Sullivan E, Bushnell C. Management of menstrual migraine: a review of current abortive and prophylactic therapies. Curr Pain Headache Rep. 2010 Oct;14(5):376-84.
29. Emmenegger MJ, Gantenbein AR. Philosophical aspects of migraine: Headache treatment is a human-to-human service. Cephalalgia. 2025 May;45(5).
30. Emami F, Kamrani K, Khosroshahi N. Association between maternal migraine and infantile colic: a narrative review. BMC Pediatr. 2025 Aug 4;25(1):591.